Dipeptidyl Peptidase 4/Midline-1 Axis Promotes T Lymphocyte Motility in Atherosclerosis
- PMID: 36683148
- PMCID: PMC10037965
- DOI: 10.1002/advs.202204194
Dipeptidyl Peptidase 4/Midline-1 Axis Promotes T Lymphocyte Motility in Atherosclerosis
Abstract
T cells play a crucial role in atherosclerosis, with its infiltration preceding the formation of atheroma. However, how T-cell infiltration is regulated in atherosclerosis remains largely unknown. Here, this work demonstrates that dipeptidyl peptidase-4 (DPP4) is a novel regulator of T-cell motility in atherosclerosis. Single-cell ribonucleic acid (RNA) sequencing and flow cytometry show that CD4+ T cells in atherosclerotic patients display a marked increase of DPP4. Lack of DPP4 in hematopoietic cells or T cells reduces T-cell infiltration and atherosclerotic plaque volume in atherosclerosis mouse models. Mechanistically, DPP4 deficiency reduces T-cell motility by suppressing the expression of microtubule associated protein midline-1 (Mid1) in T cells. Deletion of either DPP4 or Mid1 inhibits chemokine-induced shape change and motility, while restitution of Mid1 in Dpp4-/- T cell largely restores its migratory ability. Thus, DPP4/Mid1, as a novel regulator of T-cell motility, may be a potential inflammatory target in atherosclerosis.
Keywords: T cell; atherosclerosis; dipeptidyl peptidase-4; midline-1; migration.
© 2023 The Authors. Advanced Science published by Wiley-VCH GmbH.
Conflict of interest statement
The authors declare no conflict of interest.
Figures








Similar articles
-
The regulatory role of DPP4 in atherosclerotic disease.Cardiovasc Diabetol. 2017 Jun 15;16(1):76. doi: 10.1186/s12933-017-0558-y. Cardiovasc Diabetol. 2017. PMID: 28619058 Free PMC article. Review.
-
Mid1 promotes synovitis in rheumatoid arthritis via ubiquitin-dependent post-translational modification.Pharmacol Res. 2024 Jul;205:107224. doi: 10.1016/j.phrs.2024.107224. Epub 2024 May 21. Pharmacol Res. 2024. PMID: 38777113
-
Dipeptidyl Peptidase 4 Inhibitors Reduce Hepatocellular Carcinoma by Activating Lymphocyte Chemotaxis in Mice.Cell Mol Gastroenterol Hepatol. 2018 Sep 11;7(1):115-134. doi: 10.1016/j.jcmgh.2018.08.008. eCollection 2019. Cell Mol Gastroenterol Hepatol. 2018. PMID: 30510994 Free PMC article.
-
Dipeptidyl peptidase-4 inhibition: insights from the bench and recent clinical studies.Curr Opin Lipidol. 2016 Oct;27(5):484-92. doi: 10.1097/MOL.0000000000000340. Curr Opin Lipidol. 2016. PMID: 27472408 Free PMC article. Review.
-
Dipeptidyl peptidase 4 inhibition sensitizes radiotherapy by promoting T cell infiltration.Oncoimmunology. 2023 Oct 12;12(1):2268257. doi: 10.1080/2162402X.2023.2268257. eCollection 2023. Oncoimmunology. 2023. PMID: 37849962 Free PMC article.
Cited by
-
Association of the rs12617656 C/T genetic variant of the DPP4 gene with in-stent restenosis in Mexican population: a cohort study.Arch Cardiol Mex. 2024 Oct 16;95(1):34-41. doi: 10.24875/ACM.24000065. Arch Cardiol Mex. 2024. PMID: 39413436 Free PMC article.
-
Midline-1 regulates effector T cell motility in experimental autoimmune encephalomyelitis via mTOR/microtubule pathway.Theranostics. 2024 Jan 20;14(3):1168-1180. doi: 10.7150/thno.87130. eCollection 2024. Theranostics. 2024. PMID: 38323310 Free PMC article.
References
-
- a) White W. B., Cannon C. P., Heller S. R., Nissen S. E., Bergenstal R. M., Bakris G. L., Perez A. T., Fleck P. R., Mehta C. R., Kupfer S., Wilson C., Cushman W. C., Zannad F., Investigators E., N. Engl. J. Med. 2013, 369, 1327; - PubMed
- b) Scirica B. M., Bhatt D. L., Braunwald E., Steg P. G., Davidson J., Hirshberg B., Ohman P., Frederich R., Wiviott S. D., Hoffman E. B., Cavender M. A., Udell J. A., Desai N. R., Mosenzon O., McGuire D. K., Ray K. K., Leiter L. A., Raz I., Committee S.‐T. S., Investigators , N. Engl. J. Med. 2013, 369, 1317; - PubMed
- c) Green J. B., Bethel M. A., Armstrong P. W., Buse J. B., Engel S. S., Garg J., Josse R., Kaufman K. D., Koglin J., Korn S., Lachin J. M., McGuire D. K., Pencina M. J., Standl E., Stein P. P., Suryawanshi S., Van de Werf F., Peterson E. D., Holman R. R., Group T. S., N. Engl. J. Med. 2015, 373, 232; - PubMed
- d) Rosenstock J., Kahn S. E., Johansen O. E., Zinman B., Espeland M. A., Woerle H. J., Pfarr E., Keller A., Mattheus M., Baanstra D., Meinicke T., George J. T., von Eynatten M., McGuire D. K., Marx N., Investigators C., JAMA, J. Am. Med. Assoc. 2019, 322, 1155; - PMC - PubMed
- e) Rosenstock J., Perkovic V., Johansen O. E., Cooper M. E., Kahn S. E., Marx N., Alexander J. H., Pencina M., Toto R. D., Wanner C., Zinman B., Woerle H. J., Baanstra D., Pfarr E., Schnaidt S., Meinicke T., George J. T., von Eynatten M., McGuire D. K., Investigators C., JAMA, J. Am. Med. Assoc. 2019, 321, 69. - PMC - PubMed
-
- Bethel M. A., Patel R. A., Merrill P., Lokhnygina Y., Buse J. B., Mentz R. J., Pagidipati N. J., Chan J. C., Gustavson S. M., Iqbal N., Maggioni A. P., Öhman P., Poulter N. R., Ramachandran A., Zinman B., Hernandez A. F., Holman R. R., Group E. S., Lancet Diabetes Endocrinol. 2018, 6, 105. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous